Cold Agglutinin Disease: Improved Understanding of Pathogenesis Helps Define Targets for Therapy

11Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

The last 2 decades have seen great progress in understanding the pathogenesis of cold agglutinin disease (CAD) and development of effective therapies. Cold agglutinins can cause hemolytic anemia as well as peripheral circulatory symptoms such as acrocyanosis. We distinguish CAD, a well-defined clinicopathologic entity, from secondary cold agglutinin syndrome. This review addresses the histopathologic, immune phenotypic, and molecular features that allow CAD to be classified as a distinct clonal lymphoproliferative disorder of the bone marrow, recently recognized in the WHO classification. We discuss recent data on the possible overlap or distinction between CAD and Waldenström’s macroglobulinemia. Two major steps in the pathogenesis of CAD are identified: clonal B-cell lymphoproliferation (leading to monoclonal IgM production) and complement-mediated hemolysis. Each of these steps constitutes a target for treatment. Established as well as novel and experimental therapies are reviewed.

References Powered by Scopus

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia

1078Citations
N/AReaders
Get full text

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

834Citations
N/AReaders
Get full text

Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

815Citations
N/AReaders
Get full text

Cited by Powered by Scopus

ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies

36Citations
N/AReaders
Get full text

The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket?

19Citations
N/AReaders
Get full text

Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease

8Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Berentsen, S., D’Sa, S., Randen, U., Małecka, A., & Vos, J. M. I. (2022, December 1). Cold Agglutinin Disease: Improved Understanding of Pathogenesis Helps Define Targets for Therapy. Hemato. Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/hemato3040040

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

60%

Professor / Associate Prof. 1

20%

Lecturer / Post doc 1

20%

Readers' Discipline

Tooltip

Medicine and Dentistry 6

67%

Agricultural and Biological Sciences 1

11%

Biochemistry, Genetics and Molecular Bi... 1

11%

Immunology and Microbiology 1

11%

Article Metrics

Tooltip
Mentions
News Mentions: 5
Social Media
Shares, Likes & Comments: 26

Save time finding and organizing research with Mendeley

Sign up for free